BACKGROUND: Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence. METHODS: We investigated predictors of toxicity-related treatment modification during the first year of CART in 1318 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from the Swiss HIV Cohort Study who began treatment between January 1, 2005, and June 30, 2008. RESULTS: The total rate of treatment modification was 41.5 (95% confidence interval [CI], 37.6-45.8) per 100 person-years. Of these, switches or discontinuations because of drug toxicity occurred at a rate of 22.4 (95% CI, 19.5-25.6) per 100 person-years. The most frequent toxic effects were gastrointestinal tract intolerance (28.9%), hypersensitivity (18.3%), central nervous system adverse events (17.3%), and hepatic events (11.5%). In the multivariate analysis, combined zidovudine and lamivudine (hazard ratio [HR], 2.71 [95% CI, 1.95-3.83]; P < .001), nevirapine (1.95 [1.01-3.81]; P = .050), comedication for an opportunistic infection (2.24 [1.19-4.21]; P = .01), advanced age (1.21 [1.03-1.40] per 10-year increase; P = .02), female sex (1.68 [1.14-2.48]; P = .009), nonwhite ethnicity (1.71 [1.18-2.47]; P = .005), higher baseline CD4 cell count (1.19 [1.10-1.28] per 100/microL increase; P < .001), and HIV-RNA of more than 5.0 log(10) copies/mL (1.47 [1.10-1.97]; P = .009) were associated with higher rates of treatment modification. Almost 90% of individuals with treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less than 50 copies/mL at 12 months compared with 87% of those continuing CART (P = .56). CONCLUSIONS: Drug toxicity remains a frequent reason for treatment modification; however, it does not affect treatment success. Close monitoring and management of adverse effects and drug-drug interactions are crucial for the durability of CART.
BACKGROUND: Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence. METHODS: We investigated predictors of toxicity-related treatment modification during the first year of CART in 1318 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from the Swiss HIV Cohort Study who began treatment between January 1, 2005, and June 30, 2008. RESULTS: The total rate of treatment modification was 41.5 (95% confidence interval [CI], 37.6-45.8) per 100 person-years. Of these, switches or discontinuations because of drug toxicity occurred at a rate of 22.4 (95% CI, 19.5-25.6) per 100 person-years. The most frequent toxic effects were gastrointestinal tract intolerance (28.9%), hypersensitivity (18.3%), central nervous system adverse events (17.3%), and hepatic events (11.5%). In the multivariate analysis, combined zidovudine and lamivudine (hazard ratio [HR], 2.71 [95% CI, 1.95-3.83]; P < .001), nevirapine (1.95 [1.01-3.81]; P = .050), comedication for an opportunistic infection (2.24 [1.19-4.21]; P = .01), advanced age (1.21 [1.03-1.40] per 10-year increase; P = .02), female sex (1.68 [1.14-2.48]; P = .009), nonwhite ethnicity (1.71 [1.18-2.47]; P = .005), higher baseline CD4 cell count (1.19 [1.10-1.28] per 100/microL increase; P < .001), and HIV-RNA of more than 5.0 log(10) copies/mL (1.47 [1.10-1.97]; P = .009) were associated with higher rates of treatment modification. Almost 90% of individuals with treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less than 50 copies/mL at 12 months compared with 87% of those continuing CART (P = .56). CONCLUSIONS:Drug toxicity remains a frequent reason for treatment modification; however, it does not affect treatment success. Close monitoring and management of adverse effects and drug-drug interactions are crucial for the durability of CART.
Authors: Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong Journal: Can J Hosp Pharm Date: 2012-03
Authors: Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Craig D Sykes; Angela Kashuba; Kristy M Ainslie Journal: Pharm Res Date: 2016-05-06 Impact factor: 4.200
Authors: Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn Journal: PLoS One Date: 2010-06-01 Impact factor: 3.240
Authors: Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard Journal: PLoS One Date: 2010-10-12 Impact factor: 3.240
Authors: Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Joseph J Eron; Susan L Koletar; Richard D Moore; Anne Zinski; Stephen R Cole; Peter Hunt; Heidi M Crane; James Kahn; William C Mathews; Kenneth H Mayer; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: M Platten; R Linnemann; T Kümmerle; N Jung; C Wyen; K Ehren; S Gravemann; D Gillor; O A Cornely; J Fischer; C Lehmann; J K Rockstroh; G Fätkenheuer; J J Vehreschild Journal: Infection Date: 2014-06-26 Impact factor: 3.553